Effects of Salbutamol on the Treatment of Transient Tachypnea of the Newborn

Abstract

Background: This study aimed to evaluate the safety and efficacy of inhaled salbutamol for the treatment of Transient Tachypnea of the Newborn (TTN). Methods: Totally, 80 neonates with TTN were randomly assigned into two groups of treatment and placebo. The treatment and placebo groups received one dose of nebulized salbutamol (dose of 0.15 ml/kg in 2 ml of normal saline) and only 2 ml 0.9% normal saline without salbutamol, respectively. Before starting the study and30, 60 min, and 4 h after nebulization, the respiratory and heart rates, oxygen saturation, a fraction of inspired oxygen, respiratory distress score, the arterial blood gas(after 4 hours), and the time of hospital stay evaluated. The data were analyzed in SPSS software (version 23) through Fisher's exact test, Mann-Whitney U test, and ANOVA. Results: There were no significant differences between the case and control groups with regard to gender, gestational age, birth weight, mother's history of asthma, type of delivery, first-and fifth-minute Apgar, pneumothorax, and respiratory rates. The duration of tachypnea, hospital stay, oxygen therapy, and the time of initiating enteral feeding were shorter in the case group compared to the control group. Conclusion: The administration of the salbutamol can significantly improve respiratory distress following 4 h and reduce the duration of hospital stay, tachypnea, and the time of enteral feeding.